Core Insights - Mingyu Pharmaceutical Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities as joint sponsors [1] - The company, established in 2018, is a biotechnology innovator with a dual growth engine: a robust clinical-stage oncology product portfolio based on proprietary antibody-drug conjugate (ADC) platforms and a novel PD-1/VEGF bispecific antibody (bsAb) [1] - As of November 16, 2025, the company has 13 candidate products in its pipeline, with 10 in clinical stages, and expects to generate revenue from its autoimmune projects soon [1] - The oncology projects focus on advancing ADC monotherapy for later-line treatment and exploring combination therapies with PD-1/VEGF bispecific antibodies to innovate first-line cancer treatment [1]

Core Insights - Mingyu Pharmaceutical Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities acting as joint sponsors [1] - The company, established in 2018, is a biotechnology innovation enterprise with a dual growth engine: a robust clinical-stage oncology product portfolio based on proprietary antibody-drug conjugate (ADC) platform and a novel PD-1/VEGF bispecific antibody (bsAb) [1] - As of November 16, 2025, the company has 13 candidate products in its pipeline, with 10 in clinical stages, and expects to generate revenue from its autoimmune projects soon [1] - The oncology projects focus on advancing ADC monotherapy for later-line treatment and exploring combination therapies with PD-1/VEGF bispecific antibodies to innovate first-line cancer treatment [1]

Investment Rating - The investment rating for the company is positioned in the mid-to-lower range, with an AHP score of 2.38, placing it in the 38.9% percentile of the overall score [2][5]. Core Insights - The company, Baiaosaitu, is a leading preclinical CRO and biotechnology firm, focusing on gene editing, model animal sales, preclinical pharmacology and efficacy evaluation services, and antibody development. The gene editing technology is a significant foundation for its business, having developed proprietary CRISPR/EGE technology that enhances gene editing efficiency by nearly 20 times, significantly reducing commercial application costs [2][12]. - The company has expanded its business into innovative model animal sales, having developed over 4,300 gene-edited animals and cell models, including more than 1,700 humanized mice. The establishment of a production center compliant with AAALAC international standards supports large-scale breeding and supply of model animals [12][30]. - The company has established a comprehensive pharmacology and efficacy evaluation system, serving approximately 950 partners globally and completing over 6,350 drug evaluation projects. It has collaborations with 9 of the top 10 global pharmaceutical companies in the pharmacology and efficacy sector [2][18]. Summary by Sections AHP Score and Expected Allocation Ratio - The AHP score for Baiaosaitu is 2.38, indicating a mid-to-lower performance level in the AHP model [5][6]. Company Fundamentals and Highlights - Baiaosaitu has built platforms for gene editing, model animal breeding, preclinical pharmacology evaluation, and antibody drug development, evolving from a single-service biotechnology company to a leading biopharmaceutical enterprise [6][12]. - The company’s revenue composition shows that model animal sales accounted for approximately 44% of total revenue in the first half of 2025, followed by antibody development and preclinical pharmacology services [7][8]. Financial Comparison with Peers - From 2022 to the first half of 2025, Baiaosaitu's revenue was lower than that of comparable companies, with revenues of 5.34, 7.17, 9.80, and 6.21 billion yuan respectively. However, the net profit turned positive in 2024, with a net profit margin that improved over time [22][24]. - The company’s gross margin was relatively high, with figures of 73.38%, 70.59%, 77.67%, and 74.39% from 2022 to the first half of 2025, outperforming the average of comparable companies [24][25]. Fundraising Projects and Development Vision - The company plans to raise funds for projects including the construction of a drug early research service platform, antibody drug research and evaluation projects, and preclinical research projects, which are expected to enhance its core competitiveness and solidify its industry position [30][31].

Investment Rating - The report assigns a rating of "Subscribe" for the company, with an AHP score of 2.38, placing it in the 38.9% percentile of the AHP model [7][8]. Core Insights - The company, BaiAoSaiTu, is positioned as a leading preclinical CRO and biotechnology firm, with a focus on gene editing, model animal sales, preclinical pharmacology and efficacy evaluation services, and antibody development [8][9]. - The company has developed proprietary CRISPR/EGE technology that enhances gene editing efficiency by nearly 20 times, significantly reducing commercial application costs [13][14]. - BaiAoSaiTu has established a comprehensive preclinical pharmacology and efficacy evaluation system, collaborating with nine of the top ten global pharmaceutical companies [18][20]. - The company has turned profitable in 2024, with improving profitability metrics and a richer variety of mouse strains compared to peers [26][28]. Summary by Sections 1. AHP Score and Expected Allocation Ratio - BaiAoSaiTu's AHP score is 2.38, indicating a mid-to-low level performance in the AHP model [7][8]. 2. Fundamental Highlights and Features 2.1 Gene Editing Technology and Innovative Model Animal Development - BaiAoSaiTu has built platforms for gene editing and model animal breeding, evolving from a single service provider to a leading biopharmaceutical enterprise [8][9]. - The company has developed over 4,300 gene-edited animals and cell models, including more than 1,700 humanized mice [14][15]. 2.2 Antibody and Drug Collaboration Development - The company has created the RenMice platform, known for its high humanization level, facilitating the discovery and development of diverse antibody molecules [16][17]. - BaiAoSaiTu's "Thousand Mice, Ten Thousand Antibodies" initiative aims to discover antibodies against over 1,000 potential drug targets, enhancing its antibody library [17][18]. 2.3 Expansion of Preclinical Pharmacology and Efficacy Evaluation Services - BaiAoSaiTu has established a robust pharmacology and efficacy evaluation system, serving over 950 partners and completing more than 6,350 drug evaluation projects [20][21]. 3. Comparable Company Financial Metrics 3.1 Diverse Product Involvement and Rich Mouse Strain Resources - BaiAoSaiTu's humanized mouse strains exceed 1,700, compared to its peers, providing a competitive edge in preclinical evaluations [25][24]. 3.2 Revenue and Profitability Comparison - The company's revenue from 2022 to 2025 H1 was lower than peers, but it achieved profitability in 2024, with a compound annual growth rate of 35.52% [26][27]. 3.3 Higher Gross Margin and Net Profitability - BaiAoSaiTu's gross margin from 2022 to 2025 H1 averaged above 70%, with a net profit margin improving to 7.73% in 2025 H1, outperforming comparable drug development companies [28][29]. 3.4 R&D Expense Ratio Comparison - The company's R&D expense ratio was above the industry average in 2022 and 2023, reflecting its commitment to extensive research and development [31][32]. 4. Fundraising Projects and Development Vision - The company plans to raise funds for early drug development service platform construction, antibody drug research and evaluation, and preclinical research projects, enhancing its core competitiveness [34][35].

Core Insights - The research team at the Tianjin Institute of Industrial Biotechnology has made significant advancements in the field of cellulose-derived starch synthesis, achieving a theoretical yield increase from 50% to 100% through innovative energy cycle reconstruction and enzyme stability improvements [1][2]. Group 1: Research Achievements - The team has successfully restructured the synthetic pathway for cellulose to starch conversion, addressing carbon loss issues and enhancing the overall yield [1]. - By innovatively designing glucose recovery and activation mechanisms, the team has fundamentally improved the efficiency of starch production [1]. - The real conversion rate of cellulose to starch has been enhanced to 93.3% through systematic optimization of reaction factors [1]. Group 2: Product Characteristics - The starch produced is pure linear starch with highly controllable polymerization degrees and a narrow molecular weight distribution, offering superior structural uniformity compared to naturally extracted starch [2]. - This newly synthesized starch has unique application potential in food, pharmaceuticals, and materials, particularly in chiral separation technologies [2].

Group 1: Company Overview - Moer Thread is a leading company in the domestic GPU field, recognized as one of the few enterprises with full-function GPU R&D capabilities, and will become the "first domestic GPU stock" upon listing [1] - The company has successfully launched four generations of GPU architecture, covering various application areas including AI computing, high-performance computing, and graphics rendering [2] - Bai Ao Sai Tu is a global leader in innovative technology-driven biotechnology, focusing on preclinical CRO and drug development services based on self-developed gene editing technology [3] Group 2: Financial Performance - Moer Thread's projected revenues for 2022, 2023, and 2024 are 0.46 billion, 1.24 billion, and 4.38 billion respectively, with net losses of -1.894 billion, -1.703 billion, and -1.618 billion [2] - Bai Ao Sai Tu's projected revenues for the same period are 5.34 billion, 7.17 billion, and 9.8 billion, with net losses of -0.602 billion, -0.383 billion, and a profit of 0.034 billion in 2024 [4] Group 3: Fundraising and Investment Plans - Moer Thread plans to use the funds raised for the development of next-generation AI training and inference chips, graphics chips, and AISoC chips, as well as to supplement working capital [2] - Bai Ao Sai Tu intends to invest the raised funds in early drug development service platform construction, antibody drug R&D and evaluation projects, and preclinical R&D projects [4]

Core Insights - The research team at the Tianjin Institute of Industrial Biotechnology has made significant advancements in the field of cellulose-to-starch conversion, achieving a theoretical starch yield increase from 50% to 100% through innovative energy cycle reconstruction and enzyme stability improvements [1][2]. Group 1: Research Achievements - The team has successfully restructured the synthetic pathway for cellulose utilization, addressing the carbon loss issue and enhancing the theoretical yield of starch [1]. - By innovating glucose recovery and activation mechanisms, the team has fundamentally improved the efficiency of the conversion process [1]. - The actual conversion rate from cellulose to starch has been raised to 93.3% through systematic optimization of various factors in the reaction system [1]. Group 2: Product Characteristics and Applications - The starch produced is pure linear starch with highly controllable polymerization degrees, narrow molecular weight distribution, and superior structural uniformity compared to naturally extracted starch [2]. - This new starch has unique application potential in food, pharmaceuticals, and materials, having already been successfully applied in chiral separation fillers for efficient separation of chiral drug molecules [2].

Group 1: Company Overview - Moer Thread is a leading company in the domestic GPU sector, recognized for its full-function GPU R&D capabilities, and will become the "first domestic GPU stock" upon listing [1][2] - The company has successfully launched four generations of GPU architecture, covering various application fields including AI computing, high-performance computing, and graphics rendering [2] - Baiaosaitu is a preclinical CRO and biotechnology company that provides innovative animal models and preclinical drug development services based on its proprietary gene editing technology [3][4] Group 2: Financial Performance - Moer Thread's projected revenues for 2022, 2023, and 2024 are 0.46 billion, 1.24 billion, and 4.38 billion respectively, with net losses of -1.894 billion, -1.703 billion, and -1.618 billion [2] - Baiaosaitu's projected revenues for the same years are 0.534 billion, 0.717 billion, and 0.98 billion, with net losses of -0.602 billion, -0.383 billion, and a profit of 0.034 billion in 2024 [4] Group 3: Fundraising and Investment Plans - Moer Thread plans to use the funds raised for the development of next-generation AI training and inference chips, graphics chips, and AISoC chips, as well as to supplement working capital [2] - Baiaosaitu intends to invest the raised funds in early-stage drug development service platform construction, antibody drug R&D and evaluation projects, and preclinical R&D projects [4]

Core Viewpoint - The article discusses the upcoming IPOs of two companies, Moer Technology and Baiaosaitu, highlighting their significance in the GPU and biotechnology sectors respectively [1][2]. Group 1: Moer Technology - Moer Technology is a leading player in the domestic GPU market and will become the "first domestic GPU stock" upon its listing [2]. - The IPO price for Moer Technology is set at 114.28 yuan per share, with a maximum subscription limit of 11,000 shares per account, requiring a market value of 110,000 yuan in the Shanghai market for full subscription [2]. - The company focuses on the research, design, and sales of GPUs and related products, aiming to provide computing acceleration platforms for AI, digital twins, and high-performance computing [2]. - Moer Technology has successfully launched four generations of GPU architectures and has a diverse product matrix covering various application fields, including AI computing, high-performance computing, and consumer entertainment [2][3]. - The company achieved revenues of 0.46 billion yuan, 1.24 billion yuan, and 4.38 billion yuan from 2022 to 2024, with net losses of -1.894 billion yuan, -1.703 billion yuan, and -1.618 billion yuan respectively [3]. Group 2: Baiaosaitu - Baiaosaitu has a maximum subscription limit of 7,500 shares per account, requiring a market value of 75,000 yuan in the Shanghai market for full subscription [4]. - The company operates as a preclinical CRO and biotechnology firm, providing innovative animal models and preclinical drug development services based on its proprietary gene editing technology [4]. - Baiaosaitu has developed a platform called RenMice for antibody discovery, targeting nearly a thousand potential drug targets, and has established partnerships with numerous well-known biotech and pharmaceutical companies [5]. - The company expects revenues of 5.34 billion yuan, 7.17 billion yuan, and 9.8 billion yuan from 2022 to 2024, with net losses of -602 million yuan, -383 million yuan, and a profit of 34 million yuan respectively [5].

Group 1: New Stock Offerings - Two new stocks will be available for subscription on the Sci-Tech Innovation Board next week: Moer Thread on November 24 and Bai Ao Sai Tu on November 28 [1] - Moer Thread's offering price is set at 114.28 yuan per share, making it the highest IPO price this year, with a total fundraising target of 8 billion yuan [1][2] - Moer Thread is expected to become the "first domestic GPU stock" upon listing, with a total market capitalization projected to reach 53.7 billion yuan [2] Group 2: Moer Thread Company Overview - Moer Thread focuses on the research, design, and sales of GPUs and related products, aiming to provide computing acceleration platforms for high-performance computing fields such as AI and digital twins [2] - The company has launched four generations of GPU architectures since its establishment in 2020, but has not yet achieved profitability, reporting losses from 2022 to 2025 [2] Group 3: Bai Ao Sai Tu Company Overview - Bai Ao Sai Tu is a leading company in the field of model animals, focusing on preclinical research and biotechnology services [3] - The company utilizes its proprietary gene editing technology to provide innovative model animals and drug development services, and has been listed in Hong Kong since 2022 [3] - Bai Ao Sai Tu has shown revenue growth from 5.34 billion yuan in 2022 to an expected 9.80 billion yuan in 2024, with a net profit turning positive in 2025 [3]